Molecular and Cellular Biochemistry

, Volume 370, Issue 1–2, pp 127–139 | Cite as

Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells

  • Chaodong Li
  • Mei Ge
  • Yu Yin
  • Minyu Luo
  • Daijie ChenEmail author


Oncogenic KRAS, an important target for antitumor therapy, contributes to pancreatic cancer tumorigenesis, progression and maintenance. However, intracellular compensation regulation can help cells to resist the targeted therapy. Gene knockdown method such as RNAi may help to understand this intracellular regulatory system and discover novel therapeutic approach. In this study, two stable transfected cell lines were constructed through lentivirus-mediated shRNA targeting KRAS of PANC-1 cells, to investigate cell response to the knockdown of KRAS. Human whole genome microarray was then used to compare the gene expression profile. As a result, ribosomal proteins L26 and L29 (RPL26 and RPL29) were dramatically upregulated by KRAS-shRNA specifically. To identify whether RPL26 or RPL29 was critical for PANC-1 cells, siRNAs against RPL26 and RPL29 were designed and transfected in vitro. The results showed that knockdown of RPL26 or RPL29 expression significantly suppressed cell proliferation, induced cell arrest at G0/G1 phase and enhanced cell apoptosis. Reactive oxygen species (ROS) assay indicated that silencing of RPL26 or RPL29 markedly decreased the intracellular ROS generation. Our findings imply that siRNA interference against RPL26 and RPL29 is of potential value for intervention of pancreatic cancer.


KRAS Lentivirus Microarray Pancreatic cancer RNA interference RPL26/RPL29 



RNA interference


Short hairpin RNA


Small interfering RNA


Reactive oxygen species


Pancreatic cancer


Fetal bovine serum


Automated cell deposition unit


Flow cytometry


Negative control


Quantitative real-time PCR


Fluorescein isothiocyanate


Propidium iodide


Phosphate-buffered saline






3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide


Dimethyl sulfoxide


Gene Ontology


Polyvinylidene fluoride



We are grateful to Dr Jianzhong Xi (Peking University, Department of Biomedical Engineering College of Engineering, Beijing, China) for lentiviruses production and critical reading of the manuscript. National New Drug Research and Development Project (Grant 2010ZX09401-403) supported this work.

Supplementary material

11010_2012_1404_MOESM1_ESM.xls (44 kb)
Supplementary material 1 (XLS 44 kb)
11010_2012_1404_MOESM2_ESM.doc (310 kb)
Supplementary material 2 (DOC 311 kb)


  1. 1.
    Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ (1998) Increasing complexity of Ras signaling. Oncogene 17:1395–1413PubMedCrossRefGoogle Scholar
  2. 2.
    McCormick F (1989) ras GTPase activating protein: signal transmitter and signal terminator. Cell 56:5–8PubMedCrossRefGoogle Scholar
  3. 3.
    Jaffee EM, Hruban RH, Canto M, Kern SE (2002) Focus on pancreas cancer. Cancer Cell 2:25–28PubMedCrossRefGoogle Scholar
  4. 4.
    Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRefGoogle Scholar
  5. 5.
    Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant cK-ras genes. Cell 53:549–554PubMedCrossRefGoogle Scholar
  6. 6.
    Shi X, Liang Z, Ren X, Liu T (2008) Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther 16:227–236PubMedGoogle Scholar
  7. 7.
    Zhao M, He H, Sun H, Ren K, Shao R (2009) Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochem Biophys Res Commun 387:239–244PubMedCrossRefGoogle Scholar
  8. 8.
    Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284PubMedCrossRefGoogle Scholar
  9. 9.
    Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627PubMedCrossRefGoogle Scholar
  10. 10.
    Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA (2005) Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-C directed therapy. Mol Cancer Res 3:413–423PubMedCrossRefGoogle Scholar
  11. 11.
    Hopfner M, Schuppan D, Scherubl H (2008) Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 14:1–14PubMedCrossRefGoogle Scholar
  12. 12.
    Moffat J, Grueneberg DA, Yang X et al (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124:1283–1298PubMedCrossRefGoogle Scholar
  13. 13.
    Kenneth JL, Thomas DS (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-∆∆ Ct method. Methods 25:402–408CrossRefGoogle Scholar
  14. 14.
    Jiang R, Cabras G, Sheng W, Zeng Y, Ooka T (2009) Synergism of BARF1 with Ras induces malignant transformation in primary primate epithelial cells and human nasopharyngeal epithelial cells. Neoplasia 11:964–973PubMedGoogle Scholar
  15. 15.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRefGoogle Scholar
  16. 16.
    Ruggero D, Pandolfi PP (2003) Does the ribosome translate cancer? Nat Rev Cancer 3:179–192PubMedCrossRefGoogle Scholar
  17. 17.
    Amsterdam A, Sadler KC, Lai K, Farrington S, Bronson RT, Lees JA, Hopkins N (2004) Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol 2:690–698CrossRefGoogle Scholar
  18. 18.
    Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8:579–591PubMedCrossRefGoogle Scholar
  19. 19.
    DeNicola GM, Karreth FA, Humpton TJ et al (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475:106–109PubMedCrossRefGoogle Scholar
  20. 20.
    Fang J, Seki T, Maeda H (2009) Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 61:290–302PubMedCrossRefGoogle Scholar
  21. 21.
    Friday BB, Adjei AA (2005) K-ras as a target for cancer therapy. Biochim Biophys Acta 1756:127–144PubMedGoogle Scholar
  22. 22.
    Ji Z, Mei FC, Lory PL, Gilbertson SR, Chen Y, Cheng X (2009) Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer. Front Biosci 14:2904–2910PubMedCrossRefGoogle Scholar
  23. 23.
    Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553PubMedCrossRefGoogle Scholar
  24. 24.
    Lee NS, Dohjima T, Bauer G et al (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20:500–505PubMedGoogle Scholar
  25. 25.
    Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P (2006) A versatile tool for conditional gene expression and knockdown. Nat Methods 3:109–116PubMedCrossRefGoogle Scholar
  26. 26.
    Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243–247PubMedCrossRefGoogle Scholar
  27. 27.
    Links M, Brown R (1999) Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Mol Med 1:1–21Google Scholar
  28. 28.
    Naito S, Yokomizo A, Koga H (1999) Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol 6:427–439PubMedCrossRefGoogle Scholar
  29. 29.
    Warner JR, McIntosh KB (2009) How common are extraribosomal functions of ribosomal proteins? Mol Cell 34:3–11PubMedCrossRefGoogle Scholar
  30. 30.
    Takagi M, Absalon MJ, McLure KG, Kastan MB (2005) Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123:49–63PubMedCrossRefGoogle Scholar
  31. 31.
    Wang Y, Cheong D, Chan S, Hooi SC (1999) Heparin/heparan sulfate interacting protein gene expression is up-regulated in human colorectal carcinoma and correlated with differentiation status and metastasis. Cancer Res 59:2989–2994PubMedGoogle Scholar
  32. 32.
    Liu JJ, Huang BH, Zhang J, Carson DD, Hooi SC (2006) Repression of HIP/RPL29 expression induces differentiation in colon cancer cells. J Cell Physiol 207:287–292PubMedCrossRefGoogle Scholar
  33. 33.
    Liu JJ, Zhang J, Ramanan S, Julian JA, Carson DD, Hooi SC (2004) Heparin/heparan sulfate interacting protein plays a role in apoptosis induced by anticancer drugs. Carcinogenesis 25:873–879PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Chaodong Li
    • 1
    • 2
  • Mei Ge
    • 2
    • 3
  • Yu Yin
    • 2
    • 3
  • Minyu Luo
    • 2
  • Daijie Chen
    • 1
    Email author
  1. 1.School of BiotechnologyEast China University of Science and TechnologyShanghaiPeople’s Republic of China
  2. 2.Shanghai Laiyi Center for Biopharmaceutical R&DShanghaiPeople’s Republic of China
  3. 3.Shanghai Jiao Tong UniversityShanghaiPeople’s Republic of China

Personalised recommendations